版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Introduction Case Discussion,case,discussion,introduction,SNTCS,sino nasal terato carcino sarcoma,< 80 cases reported,case,discussion,introduction,History,Vencent J. HyamsDirector of the Otolaryngic Patho
2、logy branch of the Armed Forces Institute of Pathology,1968-1984,Teratoid carcinosarcoma ?Mixed mesodermal tumour ? Malignant teratoma and blastomas ?,1984,,case,discussion,introduction,Characteristics,T1-weighted MR
3、reveals a soft tissue filling the left ethmoid sinus, as uniformly high signal (*), and effusion (white arrowhead) in the left sphenoid sinus. Takasaki, K.,2006,Epithelial glandular carcinoma (at right) and osteosarcoma
4、 component (at left). (hematoxylin-eosin, original magnification x40). Smith, S. L.,2008,Endoscopic examination showing a left sinonasal tumor in the left middle turbinate. M, middle turbinate; S, nasal septum. S
5、u, Y. Y., 2010,Treatment,case,discussion,introduction,Patients generally present with locally advanced-stage diseasethe highly malignant, aggressive biological behavior the presence of air filled paranasal spaces permi
6、ts silent growth Distant metastasis of SNTCS is unusual and the most common cause of treatment failure is local recurrenceSurgical excision and postoperative radiotherapy has become the most widely accepted
7、 therapeutic plan,Introduction Case Discussion,HPI,introduction,discussion,case,42-year-old man Two weeks history of progressive left nasal obstruction and intermittent nasal bleedingNasal examination showed a mod
8、erately firm, reddish-purple mass in the left meatusBiopsy of the tumor revealed a heterogeneous admixture of epithelial and mesenchymal elements, suggesting SNTCS,Teratocarcinosarcoma Teratocarcinosarcoma consists of t
9、wo components, epithelial and mesenchymal (hematoxylin-eosin, original magnification ×200),cT3N0M0,MRI,introduction,discussion,case,MRI revealed a soft tissue filling the left meatus, maxillary and ethmoid sinus, a
10、nd effusion in the left maxillary sinus,introduction,discussion,case,Anterior craniofacial resectionIMRTGTV included the residual gross disease in the nasal cavity and paranasal sinusCTV-60 includes the GTV with a 5~1
11、0 mm margin, the whole nasal cavity and the involved paranasal sinusCTV-54 high-risk local structures (including the whole nasopharynx, lower half of sphenoid sinus, et al)lymphatic regions (including ipsilateral lymp
12、h node levels IB, II, III and VA)A 3-mm margin was added to produce PTVsPTV-66 was prescribed to 66 Gy with 2.2 Gy/fractionPTV-60 was prescribed to 60 Gy with 2.0 Gy/fractionPTV-54 was prescribed to 54 Gy with 1.8 G
13、y/fraction,Treatment,Follow-up,introduction,discussion,case,Now 3.5 years have passed since the irradiation therapyNo severe dry-eye syndrome, and other severe radiation-induced ocular toxicities happenedNo evidence
14、of recurrence or metastasis,Introduction Case Discussion,,,,Shoulders ?,introduction,case,discussion,Sinonasal tumors,Frontal SinusMaxillary SinusEthmoid SinusSpenoid Sinus,1,2,3,4,,,,,Challenge !,introduction,ca
15、se,discussion,IMRT,introduction,case,discussion,3-beam conventional 2D,6-beam conventional 3D conformal,7-beam IMRT,A dosimetry comparison between (a) a 3-beam conventional 2D treatment, (b) a 6-beam conventional 3D conf
16、ormal RT treatment, and (c) a 7-beam IMRT treatment. The PTV is represented by the solid red line. The 100% and 70% of the prescription dose are shown by the green and red colour-washed areas. A better dose conformity to
17、 the PTV can be achieved in the IMRT treatment.,Ghent Experience,introduction,case,discussion,2009,Madani, I., 2009,Dose–volume Constraints,introduction,case,discussion,Madani, I., 2009,Visual Pathway Dose,introduction,c
18、ase,discussion,,,,,,,Madani, I., 2009,Acute Toxicity,introduction,case,discussion,,Madani, I., 2009,,,Studies Reported,introduction,case,discussion,,,,,,,,,,,,,Madani, I., 2009,CTV Delineation,introduction,case,discussio
19、n,Implementation Strategy,2001,introduction,case,discussion,Claus, F.,2001,introduction,case,discussion,“Compartment-related CTV Definition”,In those regions where GTV was flanked by intact bone, no margin was addedIn
20、those regions where GTV invaded compartments enclosed by bone, like other paranasal sinuses, or extended up to their ostia, the whole compartment was included in the CTV contoursIn those regions where GTV invaded radio
21、logically defined spaces known to resist poorly invasion by malignant tumors (e.g., masticator or parapharyngeal spaces), the entire space was added,Claus, F.,2001,Cervical Lymph Nodes,Duthoy, W.,2005,introduction,case,d
22、iscussion,2005,LN Recurrence,Duthoy, W.,2005,introduction,case,discussion,2006,introduction,case,discussion,CTV Delineation cont’,CTV Delineation cont’,“ Indeed, in absence of unambiguous information on the surgical proc
23、edure and comprehensive report of the pathological analysis, a too selective selection and delineation of the CTV may lead to an unacceptable high rate of loco-regional recurrences… ”,Vincent Gregoire, 2006,It will not b
24、e inappropriate to be generous in target volume delineation,introduction,case,discussion,Conclusion,introduction,case,discussion,,may result in a decrease in ocular toxicity,,The appropriate implementation of IMRT for si
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫(kù)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 鼻腔鼻竇橫紋肌肉瘤
- 鼻咽癌常規(guī)放射治療與調(diào)強(qiáng)放射治療的比較研究.pdf
- 宮頸癌調(diào)強(qiáng)放射治療(IMRT)的臨床研究.pdf
- 復(fù)發(fā)鼻咽癌調(diào)強(qiáng)放射治療方案設(shè)計(jì).pdf
- 鼻咽癌調(diào)強(qiáng)放射治療的遠(yuǎn)期療效與失敗模式.pdf
- 鼻咽癌調(diào)強(qiáng)放射治療靶區(qū)勾畫的基本方式建議
- 鼻咽癌調(diào)強(qiáng)放射治療與常規(guī)放療的臨床研究.pdf
- 同期推量調(diào)強(qiáng)放射治療鼻咽癌29例觀察
- 宮頸癌調(diào)強(qiáng)放射治療臨床劑量學(xué)研究.pdf
- 宮頸癌調(diào)強(qiáng)放射治療與常規(guī)放療臨床觀察.pdf
- 同步加速調(diào)強(qiáng)放射治療鼻咽癌的失敗模式分析.pdf
- 初治鼻咽癌調(diào)強(qiáng)放射治療與常規(guī)放射治療近期療效與副反應(yīng)的比較.pdf
- 分段調(diào)強(qiáng)放射治療在局部晚期鼻咽癌治療的應(yīng)用研究.pdf
- 同步加速調(diào)強(qiáng)放射治療初發(fā)鼻咽癌的臨床研究.pdf
- 鼻咽癌調(diào)強(qiáng)適形放射治療的劑量學(xué)驗(yàn)證.pdf
- 宮頸癌術(shù)后調(diào)強(qiáng)放射治療的優(yōu)勢(shì)劑量學(xué)研究.pdf
- 鼻咽癌調(diào)強(qiáng)放射治療實(shí)施過(guò)程質(zhì)量保證的研究.pdf
- 鼻腔鼻竇腫瘤鼻炎鼻竇炎
- 食管癌調(diào)強(qiáng)放射治療在治療過(guò)程中靶區(qū)變化的相關(guān)研究.pdf
- 鼻咽癌調(diào)強(qiáng)放射治療中修改靶區(qū)的必要性.pdf
評(píng)論
0/150
提交評(píng)論